Results from the Phase III MAVERICK trial support the use of brain MRI surveillance alone as the standard of care for patients with small-cell lung cancer, according to an announcement distributed via PR Newswire.

Small-cell lung cancer is an aggressive form of the disease that carries a heightened risk of spreading to the brain, and clinicians have long weighed how best to monitor and manage that risk. The MAVERICK trial examined whether relying on regular brain MRI scans to detect any spread, without additional preventive intervention, is sufficient to serve as the standard approach to patient care.

According to the announcement, the Phase III trial's findings support brain MRI surveillance alone as an appropriate standard-of-care strategy for this patient population.

The release distributed through PR Newswire did not include additional details on trial sponsorship, patient enrollment figures, study sites, or named researchers beyond the trial's title and its central finding. Further specifics about the study's methodology, statistical results, and any accompanying commentary from investigators were not provided in the material made available.

It remains unclear from the announcement when the trial was conducted, where its findings were presented or published, or what immediate implications the results may have for treatment guidelines. News organizations and medical professionals seeking additional detail may need to await further disclosures or peer-reviewed publication of the trial data.